{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.4","upperLimit":"71.6","value":"52.0"},{"groupId":"OG001","lowerLimit":"24.9","upperLimit":"69.8","value":"47.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"PFS is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by stem cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).","id":"OG000","title":"Arm A: Low-dose Dexamethasone + Stem Cell Transplantation"},{"description":"Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).\n\nOnly includes subjects who received drug.","id":"OG001","title":"Arm B: Low-dose Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Only patients who achieved at least a partial response (PR) following 4 cycles of induction were included in the analysis.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}